G. Fond, N. Resseguier, F. Schürhoff, O. Godin, M. Andrianarisoa et al., , p.1

E. Aouizerate, B. Berna, F. Capdevielle, D. Chereau, I. D'amato et al.,

J. Dubreucq, C. Faget, F. Gabayet, C. Lançon, P. M. Llorca et al., , p.3

C. Passerieux, R. Rey, A. Schandrin, M. Urbach, P. Vidailhet et al., 4 FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, 2017.

, Relationships between low-grade peripheral inflammation and psychotropic drugs in 6 schizophrenia: results from the national FACE-SZ cohort, Eur. Arch. Psychiatry Clin

. Neurosci,

G. Fond, A. Tinland, M. Boucekine, V. Girard, S. Loubière et al.,

, Prescription of potentially inappropriate psychotropic 10 drugs in homeless people with schizophrenia and bipolar disorders, p.11, 2018.

, Housing First (FHF) program, Prog. Neuropsychopharmacol. Biol. Psychiatry

,

O. Godin, M. Leboyer, A. Gaman, B. Aouizerate, F. Berna et al., , p.14

I. Chereau, J. M. Dorey, C. Dubertret, J. Dubreucq, C. Faget et al., , p.15

P. M. Llorca, D. Misdrahi, R. Rey, R. Richieri, C. Passerieux et al., , p.16

M. Urbach, P. Vidalhet, N. Girerd, and G. Fond, FACE-SZ group, Metabolic syndrome, 17 abdominal obesity and hyperuricemia in schizophrenia: Results from the FACE-SZ cohort, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02473263

, Schizophr. Res

O. Godin, M. Leboyer, F. Schürhoff, L. Boyer, M. Andrianarisoa et al., , p.20

B. Aouizerate, F. Berna, D. Capdevielle, T. D'amato, H. Denizot et al., , p.21

J. Dubreucq, C. Faget, F. Gabayet, P. M. Llorca, J. Mallet et al., , p.22

R. Rey, R. Richieri, A. Schandrin, M. Urbach, P. Vidailhet et al., 23 FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, 2017.

, Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French 25 FACE-SZ cohort, J. Psychiatr. Res, vol.94, pp.62-69

,

S. M. Grundy, Diagnosis and Management of the Metabolic Syndrome: An American 28, 2005.

, Heart Association/National Heart, Lung, and Blood Institute Scientific Statement, Circulation, vol.29, pp.2735-2752

J. Hannestad, N. Dellagioia, and M. Bloch, The effect of antidepressant medication 31 treatment on serum levels of inflammatory cytokines: a meta-analysis, 2011.

, Neuropsychopharmacology, vol.36, pp.2452-2459

S. R. Kay, A. Fiszbein, and L. A. Opler, The positive and negative syndrome scale 34 (PANSS) for schizophrenia, Schizophr. Bull, vol.13, pp.261-276, 1987.

C. A. Köhler, T. H. Freitas, M. Maes, N. Q. De-andrade, C. S. Liu et al., , p.36

B. Solmi, M. Veronese, N. Herrmann, N. Raison, C. L. Miller et al., , p.37

A. F. Carvalho, Peripheral cytokine and chemokine alterations in depression: a meta-38 analysis of 82 studies, Acta Psychiatr. Scand, vol.135, pp.373-387, 2017.

,

C. A. Köhler, T. H. Freitas, B. Stubbs, M. Maes, M. Solmi et al., , p.41

G. Morris, B. S. Fernandes, A. R. Brunoni, N. Herrmann, C. L. Raison et al., , p.42

K. L. Carvalho and A. F. , Peripheral Alterations in Cytokine and Chemokine Levels After 1, 2018.

, Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta

, Analysis. Mol. Neurobiol, vol.55, pp.4195-4206

C. Lassale, G. D. Batty, A. Baghdadli, F. Jacka, A. Sánchez-villegas et al., , p.4

T. Akbaraly, Healthy dietary indices and risk of depressive outcomes: a systematic 5 review and meta-analysis of observational studies, Mol. Psychiatry, 2018.

,

J. Micoulaud-franchi, M. Faugere, S. Weibel, C. Faget, C. Lancon et al., , vol.8

M. Cermolacce, Toward a transdiagnostic tool to evaluate depressive symptoms across 9 mental disorders: Validation of the Calgary depression rating scale in patients with major 10 depressive disorder, Psychiatry Res, vol.268, pp.68-71, 2018.

,

R. Rey, T. D'amato, L. Boyer, L. Brunel, B. Aouizerate et al., , p.13

I. Chereau, G. Chesnoy-servanin, H. Denizot, J. Dorey, C. Dubertret et al., , p.14

C. Faget, F. Gabayet, C. Lancon, J. Mallet, D. Misdrahi et al., , p.15

F. Schürhoff, M. Urbach, P. Vidailhet, P. Llorca, and G. Fond,

, Nicotine dependence is 17 associated with depression and childhood trauma in smokers with schizophrenia: results from 18 the FACE-SZ dataset, Eur. Arch. Psychiatry Clin. Neurosci, 2017.

J. Sarris, J. Murphy, D. Mischoulon, G. I. Papakostas, M. Fava et al., , p.21, 2016.

, Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses, Am. J. 22 Psychiatry, vol.173, pp.575-587

J. B. Saunders, O. G. Aasland, T. F. Babor, J. R. De-la-fuente, and M. Grant, Development 24 of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on 25, 1993.

, Early Detection of Persons with Harmful Alcohol Consumption--II, Addict. Abingdon Engl, vol.26, pp.791-804

F. Schürhoff, G. Fond, F. Berna, E. Bulzacka, O. Godin et al., , p.28

M. Andrianarisoa, L. Brunel, N. Coulon, B. Aouizerate, D. Capdevielle et al., , p.29

T. D'amato, C. Dubertret, J. Dubreucq, C. Faget, F. Gabayet et al., , p.30

C. Passerieux, C. Schandrin, A. Urbach, M. Vidailhet, P. Leboyer et al., 31 FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group, FondaMental Academic Center of Expertise for Schizophrenia, vol.33, p.32, 2018.

. L'encephale,

,

I. E. Sommer, R. Westrhenen, . Van, M. J. Begemann, L. D. Witte et al., Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With, vol.36, p.37, 2013.

, Schizophrenia: An Update, Schizophr. Bull. sbt139

M. Startup, M. C. Jackson, and S. Bendix, The concurrent validity of the Global 39 Assessment of Functioning (GAF). Br, J. Clin. Psychol, vol.41, pp.417-422, 2002.

S. Suttajit and S. Pilakanta, Prevalence of metabolic syndrome and its association with 41 depression in patients with schizophrenia, Neuropsychiatr. Dis. Treat, vol.9, pp.941-946, 2013.

,

T. Tharmaraja, D. Stahl, C. W. Hopkins, S. J. Persaud, P. M. Jones et al.,

C. D. , The Association Between Selective Serotonin Reuptake Inhibitors and Glycemia: 3 A Systematic Review and Meta-Analysis of Randomized Controlled Trials, vol.81, pp.570-583, 2019.

A. Wysoki?ski, A. Margulska, D. Strzelecki, and I. K?oszewska, Levels of C-reactive 6 protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder, 2014.

, J. Psychiatry, vol.1, issue.8